Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Mar 30, 2022BD Rhapsody™ TCR/BCR Multiomic Assay speeds discovery in autoimmune disorders, immuno-oncology and infectious diseasesFRANKLIN LAKES, N.J. (Mar 30, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, recently released the BD Rhapsody™ TCR/BCR Multiomic Assay,...
-
Mar 25, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to Newsweek's inaugural list of "America's Most Trusted...
-
Mar 21, 2022
Record date for spin-off is March 22, 2022 "When Issued" trading of embecta common stock is expected to begin on March 21, 2022, under the ticker "EMBCV" BD expects the spin-off of embecta to be...
-
Mar 16, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced that Morgan Stanley & Co. LLC ("Morgan Stanley") has commenced cash tender offers (each,...
Mar 1, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of William "Bill" Brown to its board of directors, effective Feb. 28, 2022.